Clear Cell Sarcoma of Soft Tissue

In a case report, a clear cell sarcoma patient harboring BRAF V600E mutation with distant metastases was associated with a complete response to vemurafenib monotherapy at 8 weeks of treatment. Prior t… (full text at CIViC)

PMID 26286452 · Protsenko et al., 2015 · Open in CIViC

In this study, the authors analyzed 17 clear cell sarcomas from 16 patients, along with 2 positive control cell lines and 2 melanomas as negative controls, to investigate the prevalence and types of E… (full text at CIViC)

PMID 19561568 · Wang et al., 2009 · Open in CIViC

In this 2018 study by Keiko Segawa et al., the authors analyzed 22 tumors, including 16 clear cell sarcomas of soft tissue (CCSST) and 6 clear cell sarcoma–like gastrointestinal tumors (CCSLGT), to ch… (full text at CIViC)

PMID 30219084 · Segawa et al., 2018 · Open in CIViC

In this 2002 study by Cristina R Antonescu et al., 12 histologically confirmed cases of clear cell sarcoma (CCS) arising in the deep soft tissues of the extremities were analyzed to assess the prevale…

In an in vitro study, A375 cell lines expressing BRAF V600E (a known sensitizing mutation to vemurafenib) and KRAS K117N co-mutations demonstrated reduced sensitivity to vemurafenib treatment, compare… (full text at CIViC)

PMID 22205714 · Su et al., 2012 · Open in CIViC

28 patients were selected from a cohort of 43 patients with clear-cell sarcoma (CCSA) for this phase II trial. 26 of such patients presented with EWSR1 rearrangement and MET overexpression (MET+ cohor… (full text at CIViC)

PMID 28950372 · Schöffski et al., 2017 · Open in CIViC